

## **EXHIBIT H-25**




RECEIVED

NOV 2 1987

GROUP 120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*h127 #25*

In re Application of:	)	I hereby certify that this
Fu-Kuen LIN	)	paper is being deposited
Serial No: 675,298	)	with the United States
Filed: November 30, 1984	)	Postal Service as First
For: Production of	)	Class mail in an envelope
Erythropoietin	)	addressed to: Commissioner
Examiner: A. Tanenholtz	)	of Patents & Trademarks,
Group Art Unit: <i>124</i>	)	Washington, D.C. 20231,
	)	on this date.
	)	<u>October 20, 1987</u>
	)	
	)	Pamela A. Simonton
	)	Registration No. 31,060
	)	Attorney for Applicants


TRANSMITTAL

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Enclosed is a Declaration as to Deposit of  
Microorganism for filing in the above referenced case.

Respectfully submitted,  
AMGEN INC.

Date *10/20/87*

  
Pamela A. Simonton  
Reg. No. 31,060


Amgen Inc.  
1900 Oak Terrace Lane  
Thousand Oaks, CA 91320  
August 21, 1987

PatFormEl

*452*

460

675298



RM PTO-1082

Case Docket No. 7183

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:  
Transmitted herewith for filing is the patent application of  
Inventor: **FU-KUEN LIN**  
For: **"PRODUCTION OF ERYTHROPOIETIN"**

- Enclosed are:  
 **Four (4)** sheets of drawing.  
 An assignment of the invention to \_\_\_\_\_ application.  
 A certified copy of a \_\_\_\_\_  
 An associate power of attorney.  
 A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	70 -20 =	50
INDEP CLAIMS	14 -3 =	11
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

SMALL ENTITY			OTHER THAN A SMALL ENTITY		
RATE	FEE	OR	RATE	FEE	
	\$150	OR		\$300	
50 x 5 =	\$ 250	OR	x10 =	\$	
11 x 15 =	\$ 165	OR	x30 =	\$	
+ 50 =	\$ 50	OR	+ 100 =	\$	
TOTAL	\$ 665	OR	TOTAL	\$	

\*If the difference in Col. 1 is less than zero, enter "0" in Col. 2

- Please charge my Deposit Account No. \_\_\_\_\_ the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- A check in the amount of \$ 665.00 to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication credit any overpayment to Deposit Account No. 13-2855. A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 CFR 1.16.  
 Any patent application processing fees under 37 CFR 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- Any patent application processing fees under 37 CFR 1.17.  
 The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (i).  
 Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,  
**MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BICKNELL**

By Michael F. Borun  
 Michael F. Borun Reg. No. 25,447  
 Two First National Plaza, Suite 2100  
 Chicago, Illinois 60603  
 (312) 346-5750

Date: November 29, 1984



Best of  
Drawings Are  
Missing :

OCT 21 1987

RECEIVED  
NOV 2 1987  
GROUP 120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	)	PRODUCTION OF ERYTHROPOIETIN
FO-KUEN LIN	)	
Serial No.: 675,298	)	Group Art Unit
Filed: November 30, 1984	)	Examiners - A. Tanenholtz

DECLARATION AS TO DEPOSIT OF MICROORGANISM

ROBERT D. WEIST, DECLARES AND SAYS:

1. That he is Secretary of Kirin-Amgen, Inc., the owner of the above-identified patent application;

2. That certain cultures have been deposited in the permanent culture collection of the American Type Culture Collection, 12031 Parklawn Drive, Rockville, Maryland, and the culture deposits meet the requirements of the Budapest Treaty for the purposes of patent procedure;

3. That said cultures were deposited, after the filing date of the above-identified patent application, on October 20, 1987 as accession numbers ATCC 40381, for a deposit of a phage clone designated phE1 at page 42 of the above-identified application, and ATCC 67545, for a deposit of a clone designated pMkE83 in E. coli as described at page 34 of the above-identified application;

4. That said cultures have been deposited under conditions which ensure that access thereto will be available during the pendency of the above-identified patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. 122;

5. That upon issuance of a patent on the above-identified patent application Kirin-Amgen, Inc. will remove any restrictions as to public availability of the culture deposit,

45B

- 2 -

and will replace the same culture deposit should it become non-able, during the period that extends thirty years from the date of the deposit, or the period of the enforceable life of the patent, or the period of five years after the last public request for the deposit, whichever period is longest; and

6. That he declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief and believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

KIRIN-AMGEN, INC.

BY: Robert D. Weist  
Robert D. Weist  
Secretary

DATED: October 20, 1987

USA

464